Molecular biomarkers of epileptogenesis

Biomarkers in Medicine

Volumn 5, Issue 5, 2011, Pages 629-633

  Pitkänen, Asla ^b,c   Lukasiuk, Katarzyna ^a  

^a NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

cerebrospinal fluid; microRNA; proteomics; serum; traumatic brain injury

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ALBUMIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CASPASE 9; CYCLIC AMP; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMIC ACID; GLYCEROL; HOMOVANILLIC ACID; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; INTERLEUKIN 1BETA; ISOPROSTANE; LACTIC ACID; MESSENGER RNA; MICRORNA; MOLECULAR MARKER; N ACETYLASPARTIC ACID; NEURON SPECIFIC ENOLASE; NORADRENALIN; PROCOLLAGEN C PROTEINASE; PROTEIN BCL 2; PROTEIN S100B; PYRUVIC ACID; TAU PROTEIN; TETRANECTIN; VITAMIN D BINDING PROTEIN;

ARTICLE; BLOOD ANALYSIS; CEREBROSPINAL FLUID ANALYSIS; EPILEPSY; EPILEPTOGENESIS; GLASGOW OUTCOME SCALE; HUMAN; MEDICAL RESEARCH; METABOLOMICS; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROIMAGING; NONHUMAN; PATHOGENESIS; PREDICTION; PROGNOSIS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; TRAUMATIC BRAIN INJURY;

BIOLOGICAL MARKERS; BRAIN INJURIES; HUMANS; METABOLOMICS; MICRORNAS; PROTEOMICS; TRANSCRIPTOME;

EID: 80054806792     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.11.67     Document Type: Article

References (50)

1. Pitkänen A, Lukasiuk K. Molecular and cellular basis of epileptogenesis in symptomatic epilepsy. Epilepsy Behav. 14(1 Suppl. 1), 16-25 (2009).
2. Pitkänen A, Lukasiuk K. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol. 10(2), 173-186 (2011).
3. Tang Y, Lu A, Aronow BJ, Sharp FR. Blood genomic responses differ after stroke, seizures, hypoglycemia, and hypoxia: blood genomic fingerprints of disease. Ann. Neurol. 50(6), 699-707 (2001). (Pubitemid 33116129)
4. Tang Y, Gilbert DL, Glauser TA, Hershey AD, Sharp FR. Blood gene expression profiling of neurologic diseases: a pilot microarray study. Arch. Neurol. 62(2), 210-215 (2005). (Pubitemid 40204742)
5. Liu DZ, Tian Y, Ander BP, et al. Brain and blood microRNA expression profiling of ischemic stroke, intracerebral hemorrhage, and kainate seizures. J. Cereb. Blood Flow Metab. 30(1), 92-101 (2010).
6. Dash PK, Zhao J, Hergenroeder G, Moore AN. Biomarkers for the diagnosis, prognosis, and evaluation of treatment efficacy for traumatic brain injury. Neurotherapeutics 7(1), 100-114 (2010).
7. Schuff N, Meyerhoff DJ, Mueller S, et al. N-acetylaspartate as a marker of neuronal injury in neurodegenerative disease. Adv. Exp. Med. Biol. 576, 241-262; discussion 361-363 (2006).
8. Kovesdi E, Luckl J, Bukovics P, et al. Update on protein biomarkers in traumatic brain injury with emphasis on clinical use in adults and pediatrics. Acta Neurochir. (Wien) 152(1), 1-17 (2010).
9. Vos PE, Lamers KJ, Hendriks JC, et al. Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology 62(8), 1303-1310 (2004). (Pubitemid 38526041)
10. Zemlan FP, Jauch EC, Mulchahey JJ, et al. C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome. Brain Res. 947(1), 131-139 (2002). (Pubitemid 34876523)
11. Raabe A, Grolms C, Keller M, Dohnert J, Sorge O, Seifert V. Correlation of computed tomography findings and serum brain damage markers following severe head injury. Acta Neurochir. (Wien) 140(8), 787-791; discussion 791-792 (1998).
12. Liliang PC, Liang CL, Weng HC, et al. Tau proteins in serum predict outcome after severe traumatic brain injury. J. Surg. Res. 160(2), 302-307 (2010).
13. Brain Trauma Foundation; American Association of Neurological Surgeons; Congress of Neurological Surgeons. Guidelines for the management of severe traumatic brain injury. J. Neurotrauma 24(Suppl. 1), S1-S106 (2007).
14. Savola O, Pyhtinen J, Leino TK, Siitonen S, Niemela O, Hillbom M. Effects of head and extracranial injuries on serum protein S100B levels in trauma patients. J. Trauma 56(6), 1229-1234; discussion 1234 (2004). (Pubitemid 38901833)
15. Pelinka LE, Harada N, Szalay L, Jafarmadar M, Redl H, Bahrami S. Release of S100B differs during ischemia and reperfusion of the liver, the gut, and the kidney in rats. Shock 21(1), 72-76 (2004).
16. Pelinka Le, Kroepfl A, Schmidhammer R, et al. Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. J. Trauma 57(5), 1006-1012 (2004). (Pubitemid 39579285)
17. Pitkänen A, Bolkvadze T, Immonen R. Anti-epileptogenesis in rodent post-traumatic epilepsy models. Neurosci. Lett. 497(3), 163-171 (2011).
18. Xiao F, Chen D, Lu Y, et al. Proteomic analysis of cerebrospinal fluid from patients with idiopathic temporal lobe epilepsy. Brain Res. 1255, 180-189 (2009).
19. Wang L, Pan Y, Chen D, et al. Tetranectin is potential biomarker in cerebrospinal fluid and serum of patients with epilepsy. Clin. Chim. Acta 411(7-8), 581-583 (2010).
20. Xiao Z, Shen L, Chen D, et al. Talin 2 concentrations in cerebrospinal fluid in patients with epilepsy. Clin. Biochem. 43(13-14), 1129-1132 (2010).
21. Bernard F, Al-Tamimi YZ, Chatfield D, Lynch AG, Matta BF, Menon DK. Serum albumin level as a predictor of outcome in traumatic brain injury: potential for treatment. J. Trauma 64(4), 872-875 (2008). (Pubitemid 351521871)
22. Mondello S, Robicsek SA, Gabrielli A, et al. aII-spectrin breakdown products (SBDPs): diagnosis and outcome in severe traumatic brain injury patients. J. Neurotrauma 27(7), 1203-1213 (2010).
23. Pineda JA, Lewis SB, Valadka AB, et al. Clinical significance of aII-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury. J. Neurotrauma 24(2), 354-366 (2007). (Pubitemid 46492156)
24. Cardali S, Maugeri R. Detection of aII-spectrin and breakdown products in humans after severe traumatic brain injury. J. Neurosurg. Sci. 50(2), 25-31 (2006). (Pubitemid 44504149)
25. Franz G, Beer R, Kampfl A, et al. Amyloid b1-42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology 60(9), 1457-1461 (2003). (Pubitemid 36554806)
26. Wagner AK, Amin KB, Niyonkuru C, et al. CSF Bcl-2 and cytochrome C temporal profiles in outcome prediction for adults with severe TBI. J. Cereb. Blood Flow Metab. 31(9), 1886-1896 (2011).
27. Darwish RS, Amiridze NS. Detectable levels of cytochrome C and activated caspase-9 in cerebrospinal fluid after human traumatic brain injury. Neurocrit. Care 12(3), 337-341 (2010).
28. Vos PE, Jacobs B, Andriessen TM, et al. GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology 75(20), 1786-1793 (2010).
29. Lumpkins KM, Bochicchio GV, Keledjian K, Simard JM, McCunn M, Scalea T. Glial fibrillary acidic protein is highly correlated with brain injury. J. Trauma 65(4), 778-782; discussion 782-784 (2008).
30. Wiesmann M, Steinmeier E, Magerkurth O, Linn J, Gottmann D, Missler U. Outcome prediction in traumatic brain injury: comparison of neurological status, CT findings, and blood levels of S100B and GFAP. Acta Neurol. Scand. 121(3), 178-185 (2010).
31. Chiaretti A, Barone G, Riccardi R, et al. NGF, DCX, and NSE upregulation correlates with severity and outcome of head trauma in children. Neurology 72(7), 609-616 (2009).
32. Salonia R, Empey PE, Poloyac SM, et al. Endothelin-1 is increased in cerebrospinal fluid and associated with unfavorable outcomes in children after severe traumatic brain injury. J. Neurotrauma 27(10), 1819-1825 (2010).
33. Pilitsis JG, Coplin WM, ORegan MH, et al. Free fatty acids in cerebrospinal fluids from patients with traumatic brain injury. Neurosci. Lett. 349(2), 136-138 (2003). (Pubitemid 37297832)
34. McKeating EG, Andrews PJ, Mascia L. Leukocyte adhesion molecule profiles and outcome after traumatic brain injury. Acta Neurochir. Suppl. 71, 200-202 (1998). (Pubitemid 128444396)
35. Chiaretti A, Genovese O, Aloe L, et al. Interleukin 1b and interleukin 6 relationship with paediatric head trauma severity and outcome. Childs Nerv. Syst. 21(3), 185-193; discussion 194 (2005). (Pubitemid 40378394)
36. Shiozaki T, Hayakata T, Tasaki O, et al. Cerebrospinal fluid concentrations of anti-inflammatory mediators in early-phase severe traumatic brain injury. Shock 23(5), 406-410 (2005). (Pubitemid 40571662)
37. Chiaretti A, Antonelli A, Mastrangelo A, et al. Interleukin-6 and nerve growth factor upregulation correlates with improved outcome in children with severe traumatic brain injury. J. Neurotrauma 25(3), 225-234 (2008). (Pubitemid 351416742)
38. Singhal A, Baker AJ, Hare GM, Reinders FX, Schlichter LC, Moulton RJ. Association between cerebrospinal fluid interleukin-6 concentrations and outcome after severe human traumatic brain injury. J. Neurotrauma 19(8), 929-937 (2002).
39. Berger RP, Beers SR, Richichi R, Wiesman D, Adelson PD. Serum biomarker concentrations and outcome after pediatric traumatic brain injury. J. Neurotrauma 24(12), 1793-1801 (2007).
40. Yamazaki Y, Yada K, Morii S, Kitahara T, Ohwada T. Diagnostic significance of serum neuron-specific enolase and myelin basic protein assay in patients with acute head injury. Surg. Neurol. 43(3), 267-270; discussion 270-271 (1995).
41. Meric E, Gunduz A, Turedi S, Cakir E, Yandi M. The prognostic value of neuron-specific enolase in head trauma patients. J. Emerg. Med. 38(3), 297-301 (2010).
42. McKeating EG, Andrews PJ, Mascia L. Relationship of neuron specific enolase and protein S-100 concentrations in systemic and jugular venous serum to injury severity and outcome after traumatic brain injury. Acta Neurochir. Suppl. 71, 117-119 (1998). (Pubitemid 128444374)
43. Sinz EH, Kochanek PM, Heyes MP, et al. Quinolinic acid is increased in CSF and associated with mortality after traumatic brain injury in humans. J. Cereb. Blood Flow Metab. 18(6), 610-615 (1998). (Pubitemid 28262456)
44. Townend W, Ingebrigtsen T. Head injury outcome prediction: a role for protein S-100B? Injury 37(12), 1098-1108 (2006). (Pubitemid 44765014)
45. Muller K, Townend W, Biasca N, et al. S100B serum level predicts computed tomography findings after minor head injury. J. Trauma 62(6), 1452-1456 (2007). (Pubitemid 46918752)
46. Ucar T, Baykal A, Akyuz M, Dosemeci L, Toptas B. Comparison of serum and cerebrospinal fluid protein S-100B levels after severe head injury and their prognostic importance. J. Trauma 57(1), 95-98 (2004). (Pubitemid 39079236)
47. Hayakata T, Shiozaki T, Tasaki O, et al. Changes in CSF S100B and cytokine concentrations in early-phase severe traumatic brain injury. Shock 22(2), 102-107 (2004). (Pubitemid 40228186)
48. Ost M, Nylen K, Csajbok L, et al. Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 67(9), 1600-1604 (2006). (Pubitemid 44747930)
49. Brophy GM, Mondello S, Papa L, et al. Biokinetic analysis of ubiquitin C-terminal hydrolase-L1 (UCH-L1) in severe traumatic brain injury patient biofluids. J. Neurotrauma 28(6), 861-870 (2011).
50. Papa L, Akinyi L, Liu MC, et al. Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit. Care Med. 38(1), 138-144 (2010).